We Claim:

1. A compound of Formula (I), or a pharmaceutically acceptable salt thereof:



(I)

wherein:

each of R^a and R^b is independently H or $C_{1\text{-}3}$alkyl;

R^1 is H, OH, $C_{1\text{-}3}$alkyl, $OC_{1\text{-}3}$alkyl, $=CH_2$, or $=NOR^5$; or R^1 is $C_{3\text{-}6}$cycloalkyl or $C_{3\text{-}6}$heterocycloalkyl and forms a spiro group with the ring carbon to which it is attached;

each of R^{1a} and R^{1b} is independently H or $C_{1\text{-}3}$ alkyl;

R^2 comprises oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl, pyranyl, piperidinyl, piperazinyl, azepanyl, or tetrahydropyridinyl, or R^2 is selected from the group consisting of , , and , and R^6 is $C_{1\text{-}6}$alkyl, $C_{3\text{-}8}$cycloalkyl, or $C_{6\text{-}10}$aryl, or R^2 is selected from the group consisting of , , , , , , , , , , , , , , , , , , .





R^3 is C_{3-8}cycloalkyl, C_{3-8}cycloalkenyl, C_{3-7}heterocycloalkyl, or C_{2-6}heteroaryl;

R^4 is C_{6-10}aryl or C_{2-6}heteroaryl, and R^4 is optionally substituted with one to three groups independently selected from halo, C_{1-3}alkyl, C_{1-3}alkoxy, $C(O)N(R^N)_2$, and $N(R^N)_2$, and each R^N is independently H or C_{1-3}alkyl;

each R^5 independently is H, C_{1-3}alkyl, or C_{0-2}alkylene-C_{6-10}aryl;

X is C_{1-3}alkylene;

Y is SO or SO_2; and

each heterocycloalkyl, heterocycloalkenyl, and heteroaryl group independently has 1, 2, or 3 ring heteroatoms selected from N, O, and S.

2. The compound or salt of claim 1, wherein each Y is SO.

3. The compound or salt of claim 1, wherein each Y is SO_2.

4. The compound or salt of any one of claims 1-3, wherein R^a is H.

5. The compound or salt of any one of claims 1-3, wherein R^a is C_{1-3}alkyl.

6. The compound or salt of claim 5, wherein R^a is CH_3.

7. The compound or salt of any one of claims 1-6, wherein R^b is H.

8. The compound or salt of any one of claims 1-6, wherein R^b is C_{1-3}alkyl.

9. The compound or salt of claim 8, wherein R^a is CH_3.

10. The compound or salt of any one of claims 1-9, wherein R^1 is H, OH, or $=NOR^5$.

11. The compound or salt of claim 10, wherein R^5 is H or CH_3.

12. The compound or salt of any one of claims 1-9, wherein R^1 is C_{1-3}alkyl or OC_{1-3}alkyl.

13. The compound or salt of claim 12, wherein R^1 is CH_3 or OCH_3.

14. The compound or salt of claim 13, wherein R^1 is CH_3 and exhibits *S* stereochemistry.

15. The compound or salt of any one of claims 1-9, wherein R^1 is C_{3-6}cycloalkyl or C_{3-6}heterocycloalkyl and forms a spiro group with the ring carbon to which it is attached.

16. The compound or salt of claim 15, wherein R^1 together with the ring atom to which it is attached forms , , or .

17. The compound or salt of any one of claims 1-9, wherein R^1 is $=CH_2$.

18. The compound or salt of any one of claims 1-17, wherein each of R^{1a} and R^{1b} is H.

19. The compound or salt of any one of claims 1-17, wherein at least one of of R^{1a} and R^{1b} is $C_{1\text{-}3}$alkyl.

20. The compound or salt of claim 19, wherein each of R^{1a} and R^{1b} is CH_3.

21. The compound or salt of any one of claims 1-20, wherein R^2 comprises oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl, pyranyl, piperidinyl, piperazinyl, azepanyl, or tetrahydropyridinyl.

22. The compound or salt of claim 1, wherein R^2 is selected from the group consisting of , , and , and R^6 is $C_{1\text{-}6}$alkyl, $C_{3\text{-}8}$cycloalkyl, or $C_{6\text{-}10}$aryl.

23. The compound or salt of claim 22, wherein R^6 is phenyl optionally substituted with one to three groups independently selected from halo, $C_{1\text{-}3}$alkyl, $C_{1\text{-}3}$alkoxy, and CN.

24. The compound or salt of claim 1, wherein R^2 is selected from the group consisting of







25. The compound or salt of claim 24, wherein R^2 is selected from the group consisting of .



26. The compound or salt of any one of claims 1-25, wherein X is CH_2, CH_2CH_2, or $CH(CH_3)$.

27. The compound or salt of any one of claims 1-26, wherein R^3 comprises cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopentenyl, cyclohexenyl, tetrahydropyranyl, pyrrolyl, pyrazolyl, imidazolyl, tetrazolyl, furanyl, thiophenyl, thiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, pyridinyl, pyrazinyl, or pyrimidinyl.

28. The compound or salt of claim 26, wherein X-R^3 is selected from the group consisting of



29. The compound or salt of claim 28, wherein X-R^3 is



30. The compound or salt of claim 29, wherein X-R^3 is , or .

31. The compound or salt of any one of claims 1-30, wherein R^4 is substituted with one to three groups independently selected from halo, $C_{1\text{-}3}$alkyl, $C_{1\text{-}3}$alkoxy, $C(O)N(R^N)_2$, and $N(R^N)_2$, and each R^N is independently H or $C_{1\text{-}3}$alkyl.

32. The compound or salt of claim 1, wherein R^4 is selected from the group consisting of , , , and .

33. The compound or salt of claim 32, wherein R^4 is .

34. The compound or salt of claim 1, wherein:

R^a, R^b, R^{1a}, and R^{1b} are each H;

R^1 is $=CH_2$ or CH_3;

R^2 is , , , and ;

X-R^3 is , , , or ;

R^4 is ; and

each Y is SO_2.

35. The compound or salt of any one of claims 1-34, wherein R^1 is in a *(S)* configuration.

36. A compound listed in Table A, or a pharmaceutically acceptable salt thereof.

No.	Structure
A5	
A13	
A17	
A19	

A20	
A21	
A22	
A23	

A24	
A25	
A26	
A27	
A28	
A29	

A30	
A31	
A32	
A33	
A34	
A35	

A36	
A37	
A38	
A39	
A40	
A41	

A42	
A43	
A44	
A46	
A47	

A48	
A49	
A50	
A51	
A52	
A53	

A54	
A55	
A56	
A57	
A58	
A59	

A60	
A61	
A63	
A64	
A65	

A66	
A67	
A68	
A69	
A70	
A71	

A72	
A73	
A74	
A75	
A76	

A77	
A78	
A79	
A80	
A81	
A82	

A83	
A84	
A85	
A86	
A87	

A88	
A89	
A90	
A91	
A92	

A93	
A94	
A95	
A96	
A97	

A98	
A99	
A100	
A101	
A102	

A104	
A108	
A109	
A110	
A111	

A112	
A113	
A114	
A115	

A116	
A117	
A118	
A119	
A120	

A121	
A122	
A123	
A124	
A125	
A126	

A127	
A128	
A129	
A130	
A134	
A135	

A136	
A137	
A138	
A142	
A143	

A144	
A145	
A146	
A147	
A148	
A149	

A150	
A151	
A153	
A154	
A155	

A157	
A160	
A161	
A162	
A163	

A164	
A166	
A168	
A169	
A170	
A171	

A172	
A173	
A174	
A175	
A176	

A177	
A178	
A179	
A180	
A181	
A182	

A183	
A185	
A188	
A190	
A191	
A193	

A194	
A195	
A196	
A197	
A198	

A199	
A200	
A201	
A202	
A203	
A204	

A206	
A207	
A208	
A209	
A210	

37. The compound or salt of claim 36, wherein the compound is selected from the group consisting of:


,

,

,

,

,

,


,

,

, and

.

38. A pharmaceutical composition comprising the compound or salt of any one of claims 1-37 and a pharmaceutically acceptable carrier.

39. The compound or salt of any one of claims 1-37, or the pharmaceutical composition of claim 38, for use as a treatment of cancer.

40. The compound or salt of any one of claims 1-37, or the pharmaceutical composition of claim 38, for use as a medicament.

41. Use of the compound or salt of any one of claims 1-37 or the pharmaceutical composition of claim 38, in the manufacture of a medicament for treating inflammation in a subject, wherein a therapeutically effective amount of the medicament is to be administered to the subject.

42. Use of the compound or salt of any one of claims 1-37 or the pharmaceutical composition of claim 38, in the manufacture of a medicament for treating or preventing cancer or a precancerous condition in a subject, wherein a therapeutically effective amount of the medicament is to be administered to the subject.

43. The use of claim 42, wherein the cancer is melanoma, multiple myeloma, prostate cancer, lung cancer, pancreatic cancer, squamous cell carcinoma, leukemia, lymphoma, a neuroendocrine tumor, bladder cancer, or colorectal cancer.

44. The use of claim 42, wherein the cancer is non small cell lung carcinoma, squamous cell carcinoma, leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, lymphoma, NPM/ALK-transformed anaplastic large cell lymphoma, diffuse large B cell lymphoma, neuroendocrine tumors, breast cancer, mantle cell lymphoma, renal cell carcinoma, rhabdomyosarcoma, ovarian cancer, endometrial cancer, small cell carcinoma, adenocarcinoma, gastric carcinoma, hepatocellular carcinoma, pancreatic cancer, thyroid carcinoma, anaplastic large cell lymphoma, hemangioma, or head and neck cancer.

45. The use of claim 42, wherein the cancer is a solid tumor.

46. The use of claim 42, wherein the cancer is head and neck cancer, squamous cell carcinoma, gastric carcinoma, or pancreatic cancer.

47. Use of the compound or salt of any one of claims 1-37 or the pharmaceutical composition of claim 38, in the manufacture of a medicament for treating an autoimmune disease in a subject, wherein a therapeutically effective amount of the medicament is to be administered to the subject.

48. The use of claim 47, wherein the autoimmune disease is psoriasis, dermatitis, systemic scleroderma, sclerosis, Crohn's disease, ulcerative colitis; respiratory distress syndrome, meningitis; encephalitis; uveitis; colitis; glomerulonephritis; eczema, asthma, chronic inflammation; atherosclerosis; leukocyte adhesion deficiency; rheumatoid arthritis; systemic lupus erythematosus (SLE); diabetes mellitus; multiple sclerosis; Reynaud's syndrome; autoimmune thyroiditis; allergic encephalomyelitis; Sjorgen's syndrome; juvenile onset diabetes; tuberculosis, sarcoidosis, polymyositis, granulomatosis and vasculitis; pernicious anemia (Addison's disease); diseases involving leukocyte diapedesis; central nervous system (CNS) inflammatory disorder; multiple organ injury syndrome; hemolytic anemia; myasthenia gravis; antigen-antibody complex mediated diseases; anti-glomerular basement membrane disease; antiphospholipid syndrome; allergic neuritis; Graves' disease; Lambert-Eaton myasthenic syndrome; pemphigoid bullous; pemphigus;

autoimmune polyendocrinopathies; Reiter's disease; stiff-man syndrome; Behcet disease; giant cell arteritis; immune complex nephritis; IgA nephropathy; IgM polyneuropathies; immune thrombocytopenic purpura (ITP) or autoimmune thrombocytopenia.

49. Use of the compound or salt of any one of claims 1-37 or the pharmaceutical composition of claim 38, in the manufacture of a medicament for the treatment of an immune-related disease in a subject, wherein a therapeutically effective amount of the medicament is to be administered to the subject.

50. The use of claim 49, wherein the immune-related disease is rheumatoid arthritis, lupus, inflammatory bowel disease, multiple sclerosis, or Crohn's disease.

51. Use of the compound or salt of any one of claims 1-37 or the pharmaceutical composition of claim 38, in the manufacture of a medicament for treating neurodegenerative disease in a subject, wherein a therapeutically effective amount of the medicament is to be administered to the subject.

52. The use of claim 51, wherein the neurodegenerative disease is multiple sclerosis.

53. Use of the compound or salt of any one of claims 1-37 or the pharmaceutical composition of claim 38, in the manufacture of a medicament for treating an inflammatory disease in a subject, wherein a therapeutically effective amount of the medicament is to be administered to the subject.

54. The use of claim 53, wherein the inflammatory disease is bronchitis, conjunctivitis, myocarditis, pancreatitis, chronic cholecstitis, bronchiectasis, aortic valve stenosis, restenosis, psoriasis or arthritis.